Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays.

Shulman NS, Delgado J, Bosch RJ, Winters MA, Johnston E, Shafer RW, Katzenstein DA, Merigan TC.

J Acquir Immune Defic Syndr. 2005 May 1;39(1):78-81.

PMID:
15851917
2.

Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.

Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G, Deeks SG, Bates M, Hellmann NS, Petropoulos CJ.

AIDS. 2002 Oct 18;16(15):F41-7.

PMID:
12370521
4.

Novel recombinant phenotypic assay for clonal analysis of reverse transcriptase mutations conferring drug resistance to HIV-1 variants.

Paolucci S, Baldanti F, Zavattoni M, Gerna G.

J Antimicrob Chemother. 2004 May;53(5):766-71. Epub 2004 Mar 24.

PMID:
15044427
6.

Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors.

Harrigan PR, Mo T, Wynhoven B, Hirsch J, Brumme Z, McKenna P, Pattery T, Vingerhoets J, Bacheler LT.

AIDS. 2005 Mar 24;19(6):549-54.

PMID:
15802972
7.

Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups.

Tuaillon E, Gueudin M, Lemée V, Gueit I, Roques P, Corrigan GE, Plantier JC, Simon F, Braun J.

J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1543-9.

PMID:
15577405
8.

Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.

Shulman N, Zolopa AR, Passaro D, Shafer RW, Huang W, Katzenstein D, Israelski DM, Hellmann N, Petropoulos C, Whitcomb J.

AIDS. 2001 Jun 15;15(9):1125-32.

PMID:
11416714
9.

Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Hachiya A, Kodama EN, Sarafianos SG, Schuckmann MM, Sakagami Y, Matsuoka M, Takiguchi M, Gatanaga H, Oka S.

J Virol. 2008 Apr;82(7):3261-70. doi: 10.1128/JVI.01154-07. Epub 2008 Jan 23.

10.

NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.

Paolucci S, Baldanti F, Campanini G, Cancio R, Belfiore A, Maga G, Gerna G.

Antiviral Res. 2007 Nov;76(2):99-103. Epub 2007 Jul 2.

PMID:
17640745
11.

Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.

Zhang Z, Walker M, Xu W, Shim JH, Girardet JL, Hamatake RK, Hong Z.

Antimicrob Agents Chemother. 2006 Aug;50(8):2772-81.

12.
13.

Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine.

Uhlmann EJ, Tebas P, Storch GA, Powderly WG, Lie YS, Whitcomb JM, Hellmann NS, Arens MQ.

J Clin Virol. 2004 Nov;31(3):198-203.

PMID:
15465412
14.

Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region.

Kisic M, Mendieta J, Puertas MC, Parera M, Martínez MA, Martinez-Picado J, Menéndez-Arias L.

J Mol Biol. 2008 Oct 3;382(2):327-41. doi: 10.1016/j.jmb.2008.07.030. Epub 2008 Jul 17.

PMID:
18662701
15.
16.
17.

Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations.

Basavapathruni A, Vingerhoets J, de Béthune MP, Chung R, Bailey CM, Kim J, Anderson KS.

Biochemistry. 2006 Jun 13;45(23):7334-40.

PMID:
16752922
18.

Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.

Ren J, Nichols CE, Stamp A, Chamberlain PP, Ferris R, Weaver KL, Short SA, Stammers DK.

FEBS J. 2006 Aug;273(16):3850-60.

19.
20.

Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.

Saracino A, Monno L, Scudeller L, Cibelli DC, Tartaglia A, Punzi G, Torti C, Lo Caputo S, Mazzotta F, Scotto G, Carosi G, Angarano G.

J Med Virol. 2006 Jan;78(1):9-17.

PMID:
16299731

Supplemental Content

Support Center